JPRN-UMIN000002394已完成未知
A multicenter study of new anticancer agent for patients with advanced hepatocellular carcinoma : efficacy and safety - A multicenter study of new anticancer agent for patients with advanced hepatocellular carcinoma : efficacy and safety
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Contraindication of new anticancer agent 2) The investigator consider not suitable for the study
研究者
相似试验
进行中（未招募）
1 期
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination StudyCarcinoma, Non-Small-Cell LungNCT03381274MedImmune LLC43
已完成
1 期
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)AML, Adult RecurrentMDSNCT05829226PureTech101
终止
1 期
MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLCEGFR-mutated NSCLC (Disorder)NCT03418532Molecular Partners AG8
进行中（未招募）
1 期
Selinexor in the treatment of patients with Refractory and/or Relapsed Richter's TransformatioEUCTR2014-001240-38-GBKaryopharm Therapeutics Inc.50
进行中（未招募）
1 期
Richters TransformatioInitial and Refractory/Relapsed Richters Transformation (RT)MedDRA version: 18.0Level: PTClassification code 10058728Term: Richter's syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001240-38-DEKaryopharm Therapeutics, Inc.50